PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Irinotecan (Primary) ; Palbociclib (Primary) ; Temozolomide (Primary) ; Temozolomide
- Indications CNS cancer; Ewing's sarcoma; Medulloblastoma; Neuroblastoma; Rhabdoid tumour; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 11 Nov 2019 Planned End Date changed from 3 Dec 2023 to 16 Nov 2023.
- 20 Oct 2019 Planned End Date changed from 16 Nov 2023 to 3 Dec 2023.
- 08 Jul 2019 Planned primary completion date changed from 7 Aug 2020 to 19 Dec 2022.